by Crestone, Inc. | Sep 5, 2024 | Press Releases
Primary endpoint met with high rates of clinical cure at day 12 Very low rates of recurrence observed with CRS3123 CRS3123 was generally safe and well tolerated NIAID exercises $4.5 million option to fund phase 2 supporting studies BOULDER, CO, September 5, 2024...
by Crestone, Inc. | Feb 24, 2023 | Information
We know it can be difficult when germs like bacteria and fungi learn to fight back against the medicines designed to keep them in check. This is called antimicrobial resistance, and it’s a natural process that can unfortunately make some infections very hard...
by Crestone, Inc. | Feb 15, 2023 | Information
Developing a drug or a therapeutic regimen is a complex, long, and expensive process. Before a pharmaceutical or biotechnology company can begin marketing its products, it must undergo a rigorous review process to gain approval from the various regulatory authorities...
by Crestone, Inc. | Jan 29, 2023 | Information
The pharmaceutical industry relies heavily on small-molecule drugs to treat a variety of diseases and medical conditions [1]. Their ability to cross biological barriers, modulate multiple biological targets, and be chemically synthesized makes small-molecule drugs...
by Crestone, Inc. | Jan 19, 2023 | Information
Doctors and other healthcare workers in biotech companies in Colorado utilize patient reported outcome measures (PROMs) as a tool to evaluate a patient’s general physical and mental health. These measurements help healthcare practitioners create individualized...
